title: Is there still a role for ultrafiltration in the management of acute heart failure? CARRESS and beyond.
abstract: The Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARRESS-HF) trial was a prospective, randomized study comparing ultrafiltration versus pharmacological therapy in the treatment of acute decompensated heart failure (ADHF) complicated by cardiorenal syndrome Bart et al. (N Eng J Med 367:2296-2304, 1). The study found that ultrafiltration was inferior to pharmacological therapy, resulting in a significant increase in serum creatinine and serious adverse events while producing no significant difference in weight loss. The CARRESS trial calls into question the viability of ultrafiltration as a preferable treatment strategy in ADHF patients with cardiorenal syndrome.
authors.affiliation: Pat and Jim Calhoun Cardiology Center, UCONN Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA. jaryan@uchc.edu
authors.forename: Jason
authors.initials: J
authors.lastname: Ryan
authors.forename: Stephen
authors.initials: S
authors.lastname: Meng
mesh_terms: D000208:Acute Disease; D059347:Cardio-Renal Syndrome / Q000209:etiology / Q000628:therapy; D006333:Heart Failure / Q000150:complications / Q000628:therapy*; D006440:Hemofiltration / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D016896:Treatment Outcome